Summit Insights Group analyst Kinngai Chan upgrades Lam Research (NASDAQ:LRCX) from Hold to Buy.
Biodesix Sees FY23 Revenue Guidance Of $52M-$55M Vs. $52.51M Estimate
Guidance represents anticipated 36-44% growth over 2022 total revenue from Lung Diagnostic testing, Biopharmaceutical Services and COVID-19 testing;
Excluding 2022 COVID-19 testing